# A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

> **NCT03106428** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 67 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Multiple Myeloma
- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** MEDI7247

## Key facts

- **NCT ID:** NCT03106428
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-29
- **Primary completion:** 2020-01-03
- **Final completion:** 2020-01-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03106428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03106428, "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03106428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*